Drug

Hydroxyurea

In clinical development

Emerging researchLate-stage developmentCooling momentum

Also known as Carbamohydroxamic acid, Carbamohydroximic acid, Carbamoyl oxime, Carbamyl hydroxamate+14 more

Carbamohydroxamic acid, Carbamohydroximic acid, Carbamoyl oxime, Carbamyl hydroxamate, Droxia, Hidroxicarbamida, Hydrea, Hydroxycarbamid, Hydroxycarbamide, Hydroxycarbamidum, Hydroxyharnstoff, Mylocel, N-Carbamoylhydroxylamine, N-Hydroxyurea, Oxyurea, Siklos, Xromi, Hydroxy Urea.

RxNorm5552 ChEMBLCHEMBL467UNIIX6Q56QN5QC

Research papers

Active clinical trials

Latest activity

beta

Recent clinical, regulatory, research and industry developments relating to this drug.

T-Cell Depleted, Alternative Donor Transplant in Pediatric and Adult Patients With Severe Sickle Cell Disease (SCD) and Other Transfusion-Dependent Anemias

Clinical trial2026-08-01Primary completion · ClinicalTrials.gov

Reduced Intensity Conditioning for Haploidentical Bone Marrow Transplantation in Patients With Symptomatic Sickle Cell Disease. (BMTCTN1507)

Clinical trial2026-07-08Results posted · ClinicalTrials.gov

Frontline Ziftomenib in NPM1-Mutated or KMT2A-Rearranged Acute Myeloid Leukemia in Patients Not Eligible for Intensive Induction or Other Therapy

Clinical trial2026-07-06Results expected Q4 2027 · ClinicalTrials.gov

Randomized, Open-label, Multicenter Phase 3 Study to Assess the Efficacy and Safety of GIVinostat Versus Hydroxyurea IN JAK2V617F-positive High-risk Polycythemia Vera Patients: the GIV-IN PV TRIAL

Clinical trial2026-07-01Primary completion · ClinicalTrials.gov

REALIZING EFFECTIVENESS ACROSS CONTINENTS WITH HYDROXYUREA (REACH): A PHASE I/II PILOT STUDY OF HYDROXYUREA FOR CHILDREN WITH SICKLE CELL ANEMIA

Clinical trial2026-06-30Results posted · ClinicalTrials.gov

Safety and Efficacy of Hemoglobin F Inducers in Patients With Beta Thalassemia: a Prospective 12 Months Study

Clinical trial2026-06-29Results expected Q2 2027 · ClinicalTrials.gov

A Phase 3, Randomized, Double-blind, Active-Comparator-Controlled Clinical Study to Evaluate the Efficacy and Safety of Bomedemstat (MK-3543) Versus Hydroxyurea in Cytoreductive Therapy Naïve Essential Thrombocythemia Participants

Clinical trial2026-06-26Results expected Q3 2027 · ClinicalTrials.gov

CD83 CAR T in Relapsed or Refractory Acute Myeloid Leukemia (AML): A Phase I Trial

Clinical trial2026-06-10Results expected Q2 2028 · ClinicalTrials.gov

Leukemic transformation and second cancers in 3649 patients with high-risk essential thrombocythemia in the EXELS study.

Research2018-10-11Leukemia research

Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM): a trial for children with sickle cell anemia.

Research2017-10-19Blood

Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG).

Research2011-05-01Lancet (London, England)

Recruitment of infants with sickle cell anemia to a Phase III trial: data from the BABY HUG study.

Research2010-08-24Contemporary clinical trials

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name

Hydroxyurea

Aliases & brands

Carbamohydroxamic acidCarbamohydroximic acidCarbamoyl oximeCarbamyl hydroxamateDroxiaHidroxicarbamidaHydreaHydroxycarbamidHydroxycarbamideHydroxycarbamidumHydroxyharnstoffMylocelN-CarbamoylhydroxylamineN-HydroxyureaOxyureaSiklosXromiHydroxy Urea

RxNorm CUI

5552

ChEMBL ID

CHEMBL467

UNII

X6Q56QN5QC